The EC has opened a formal investigation into concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission will investigate whether Aspen has abused a dominant market position in breach of EU ant
The European Commission announced Monday a formal investigation into Aspen Pharmacare over suggestions that the company engaged in "excessive pricing" for five cancer medicines.